Amanda Denney, MD
Endocrinology, Diabetes & Metabolism · Cincinnati, OHNPI 1003871047
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $158,660 of the $183,185 with a category attached, or 86.6%. 33 manufacturers reported payments, led by Novo Nordisk at 55.6% of the total. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 539 payments — averaging $339.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$102K
- Lilly USA, LLC$44K
- Boehringer Ingelheim$33K
- Dexcom, Inc.$831
- AstraZeneca$631
- Sanofi-aventis U.S. LLC$512
- plus $2K from 27 others
What the payments were for
- Consulting fees$3,2312%
- Speaking & faculty fees$158,66087%
- Travel & lodging$10,2446%
- Food & beverage$11,0006%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 167 | $101,796 |
| Lilly USA, LLC | 112 | $44,484 |
| Boehringer Ingelheim | 90 | $32,520 |
| Dexcom, Inc. | 35 | $831 |
| AstraZeneca(2 entities) | 21 | $631 |
| Sanofi-aventis U.S. LLC | 20 | $512 |
| Insulet Corporation | 12 | $395 |
| Amgen | 6 | $176 |
| Novartis | 10 | $173 |
| Xeris Pharmaceuticals, Inc. | 3 | $152 |
| Boston Scientific | 1 | $145 |
| BETA Bionics, Inc. | 1 | $139 |
| Corcept Therapeutics | 7 | $138 |
| Sequel Med Tech, LLC | 1 | $138 |
| Abbott | 5 | $104 |
| Medtronic | 2 | $102 |
| AbbVie | 6 | $93 |
| Shire North American Group Inc | 5 | $85 |
| Tandem Diabetes Care, Inc. | 3 | $82 |
| Johnson & Johnson | 6 | $77 |
| Pfizer | 3 | $58 |
| Mannkind Corporation | 3 | $45 |
| Merck | 3 | $42 |
| Amryt Pharma Holdings Ltd | 2 | $41 |
| Valeritas, Inc. | 2 | $38 |
| Vivus LLC | 3 | $35 |
| Lifescan, Inc. | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $26 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Radius Health, Inc. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Senseonics, Incorporated | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$74,484
- Ozempic$55,919
- RYBELSUS$30,881
- Tresiba$6,785
- iLet Bionic Pancreas$417
- FARXIGA$372
- TZIELD$263
- WaveWriter Alpha Prime 16$145
- TWIIST$138
- DEXCOM G6 TRANSMITTER$122
- GVOKE HYPOPEN$118
- Omnipod$115
How this compares
$183,185 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 239 | $289,159 |
| MounjaroTirzepatide | 166 | $220,503 |
| JardianceEmpagliflozin | 193 | $185,446 |
| Humalog Kwikpen U-200Insulin Lispro | 29 | $123,639 |
| TrulicityDulaglutide | 73 | $116,990 |
| Somatuline DepotLanreotide Acetate | 13 | $103,713 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 86 | $90,045 |
| FarxigaDapagliflozin Propanediol | 56 | $64,004 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $34,633 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 30 | $29,695 |
| TradjentaLinagliptin | 34 | $26,566 |
| FiaspInsulin Aspart (Niacinamide) | 16 | $26,175 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $24,713 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 33 | $24,346 |
| LyumjevInsulin Lispro-Aabc | 22 | $22,435 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $44,484 | $374,224311 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $101,796 | $319,556267 claims |
| Boehringer IngelheimJardiance, Tradjenta | $32,520 | $212,012227 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $16 | $103,71313 claims |
| AstraZenecaFarxiga | $631 | $64,00456 claims |
| MerckJanuvia | $42 | $19,16120 claims |
| AbbVieSynthroid | $93 | $16,552185 claims |
| PfizerLevoxyl | $58 | $1,07340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Cincinnati
- Nelson WattsCincinnati$346K
- Shawn PeavieCincinnati$201K
- Elena ChristofidesColumbus$2.3M
- Kevin PantaloneCleveland$1.2M
- John PaesWesterville$671K
- Samuel AndersonColumbus$556K
- Bhaskar GundaboluToledo$471K
- Baker MachhadiehHamilton$304K
- Brian BurtchMentor$264K
- Allan KennedyCleveland$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.